OAM
VTGN icon

Oxford Asset Management’s VistaGen Therapeutics VTGN Stock Holding History

Oxford Asset Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-872
Closed -$39K – 2011
2018
Q4 		$39K Buy
+872
New +$47.5K ﹤0.01% 1719

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oxford Asset Management's VTGN Position: Q1 2019 in Review

Oxford Asset Management sold out of VistaGen Therapeutics (VTGN) in Q1 2019, closing a stake of 872 shares — an estimated $39K sold.

Oxford Asset Management first reported a position in VTGN in Q4 2018 and held it in 1 quarter. The position peaked at $39K in Q4 2018. 25 funds tracked by Wall St. Rank hold VTGN as of Q1 2019.

  • Oxford Asset Management reported no remaining VistaGen Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 872 VistaGen Therapeutics shares in Q1 2019, an estimated $39K.
  • Oxford Asset Management first reported a position in VistaGen Therapeutics in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's VistaGen Therapeutics position peaked at $39K in Q4 2018.
  • 25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.